

XP-002204207

AN - 1990-151821 [25]

AP - JP19880190637 19880801 JP19880190637 19880801; [Previous Publ. J02096535]

CPY - CHUS

DC - B04 B05

FS - CPI

IC - A61K37/02 ; A61K38/00

MC - B04-B04A6 B12-H01

M1 - [01] M423 M781 M903 P812 V624; 1327-U 0502-U

PA - (CHUS) CHUGAI PHARM CO LTD

PN - JP2096535 A 19900409 DW199020 000pp

- JP2632014B2 B2 19970716 DW199733 A61K38/00 006pp

PR - JP19880048632 19880303; JP19880190637 19880801

XA - C1990-066289

XIC - A61K-037/02 ; A61K-038/00

AB - J02096535 Therapeutic agent for anaemia caused from bone marrow

function, contains as active substance, human erythropoietin. Pref.

the human erythropoietin is prepd. by gene expression of gene in host,

encoding aminoacid sequence of human erythropoietin, which is obtd.

from human urine. Carcinostatic substance is cisplatin,

5-fluorouracyl, merphalan, cyclophosphamide, busulphan, cytarabine,

mercaptofurine, doxorubicin, aclarubicin, mitomycin C, actinomycin D

or etoposide. Therapeutic agent is used for redn. of side-effects of

administration of carcinostatic substance. Dose of human

erythropoietin H-EPO) is 500-100000 U/day. Therapeutic agent is in

form of intravenous or subcutaneous injection.

- USE/ADVANTAGE - For therapy of anaemia due to radiation exposure or
administration of carcinostatic substance.

- (Dwg.0/0)

DRL - 1327-U 0502-U

IW - THERAPEUTIC AGENT ANAEMIA CONTAIN HUMAN ERYTHROPOIETIN ACTIVE
SUBSTANCE CARCINOSTATIC SUBSTANCE SIDE EFFECT REDUCE

IKW - THERAPEUTIC AGENT ANAEMIA CONTAIN HUMAN ERYTHROPOIETIN ACTIVE
SUBSTANCE CARCINOSTATIC SUBSTANCE SIDE EFFECT REDUCE

NC - 001

OPD - 1988-03-03

ORD - 1990-04-09

PAW - (CHUS) CHUGAI PHARM CO LTD

TI - Therapeutic agent for anaemia - contg. human erythropoietin as active
substance, for carcinostatic substance side-effect redn. etc.